NEW YORK – Autoimmune disease firm Exagen announced on Monday that it is offering 3.7 million shares of its common stock priced at $16.25 per share.
The company said it expects proceeds from the offering to be $60.1 million. Exagen has also granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock. The offering is expected to close on March 25.
Cowen, William Blair, and Cantor Fitzgerald are acting as joint bookrunning managers for the offering, along with Canaccord Genuity. BTIG is the lead manager.